Palatin Technologies (PTN)
NASDAQ:PTN
Want to see PTN full AI Analyst Report?
PTN Stock Chart & Stats
$16.05
--
Market closed
$16.05
--
Day’s Range― - ―
52-Week Range$4.52 - $31.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.99K
Market Cap
$24.73M
Enterprise Value$354.73M
Total Cash (Recent Filing)$10.16M
Total Debt (Recent Filing)$286.66K
Price to Earnings (P/E)―
Beta-0.24
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.66
Shares Outstanding1,779,275
10 Day Avg. Volume2,746
30 Day Avg. Volume2,993
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.18
Enterprise Value/Market Cap14.34
Enterprise Value/Revenue27.53
Enterprise Value/Gross Profit27.60
Enterprise Value/Ebitda-55.67
Forecast
1Y Price Target
$47.50Price Target Upside195.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-4.24
Revenue Forecast (FY)$11.09M
Bulls Say, Bears Say
Bulls Say
Non-dilutive Partnership FundingMaterial upfronts and milestone receipts from partners provide durable non-dilutive capital, validate assets with strategic partners, and reduce near-term reliance on equity markets. This strengthens the company's ability to fund IND-enabling work and de-risks execution versus pure equity financing.
Peptide MC4R Program Advancing Toward INDProgress to an IND submission is a structural de-risking milestone: reaching IND-enabling completion and filing can materially increase optionality for partnering, licensing, or value realization and underpins medium-term commercial and regulatory strategy for obesity indications.
Low Leverage And High Gross Margin When Revenue OccursLow debt reduces financial distress risk and provides flexibility during development cycles. Very high gross margin on collaboration/licensing revenue means incremental revenue converts efficiently to gross profit, improving cash conversion from partner deals or royalties when realized.
Bears Say
Persistent Cash Burn And Negative Free Cash FlowSustained negative operating and free cash flow indicates ongoing funding needs to support R&D and operations. Over the medium term this increases the probability of additional financings, potential dilution, or the need to prioritize programs, which can constrain strategic optionality.
Limited Cash Runway And Funding DependenceA finite runway tied to expected receivables and milestone timing creates structural execution risk: delays or shortfalls would force spending cuts, partner renegotiation, or financing. That dependence can disrupt IND timelines and downstream partnering or commercialization plans.
Competitive And Timing Disadvantage Vs Approved MC4R ProductBeing years behind an approved competitor compresses addressable market and heightens the need for clear differentiation. Delays (including deprioritized earlier oral candidates) raise the risk that clinical or commercial windows narrow, reducing return potential for late entrants.
Palatin Technologies News
PTN FAQ
What was Palatin Technologies’s price range in the past 12 months?
Palatin Technologies lowest stock price was $4.52 and its highest was $31.00 in the past 12 months.
What is Palatin Technologies’s market cap?
Palatin Technologies’s market cap is $24.73M.
When is Palatin Technologies’s upcoming earnings report date?
Palatin Technologies’s upcoming earnings report date is Nov 16, 2026 which is in 165 days.
How were Palatin Technologies’s earnings last quarter?
Palatin Technologies released its earnings results on May 13, 2026. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$1.243 by $0.873.
Is Palatin Technologies overvalued?
According to Wall Street analysts Palatin Technologies’s price is currently Undervalued.
Does Palatin Technologies pay dividends?
Palatin Technologies does not currently pay dividends.
What is Palatin Technologies’s EPS estimate?
Palatin Technologies’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Palatin Technologies have?
Palatin Technologies has 1,779,275 shares outstanding.
What happened to Palatin Technologies’s price movement after its last earnings report?
Palatin Technologies reported an EPS of -$0.37 in its last earnings report, beating expectations of -$1.243. Following the earnings report the stock price went down -16.011%.
Which hedge fund is a major shareholder of Palatin Technologies?
Currently, no hedge funds are holding shares in PTN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Palatin Technologies
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.
PTN Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Balanced: The call highlighted meaningful near-term commercial validation via upfront collaboration revenue, materially reduced net loss, reduced operating cash burn, strong partnership-driven non-dilutive funding and clear progress across peptide and oral MC4R programs (including IP development). Offsetting these positives are increased operating costs, a limited cash runway to mid-2027 that creates funding risk, a deprioritized earlier oral candidate and timing/competitive risks (notably Rhythm's approved product). Clinical risk around hyperpigmentation and the need for further IND/clinic-readout milestones keep the outlook cautious.View all PTN earnings summariesPTN Stock 12 Month Forecast
Average Price Target
$47.50
▲(195.95% Upside)
Technical Analysis
Ibio
―
Phio Pharmaceuticals
―
BioRestorative Therapies
―
Addex Therapeutics
―
Bolt Biotherapeutics
―
Ownership Overview
11.15% Insiders
1.96% Mutual Funds
27.39% Other Institutional Investors
58.43% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---